Relative quantitation of glycans in cetuximab using ultra-high-performance liquid chromatography-high-resolution mass spectrometry by Pronase E digestion.


Journal

Journal of chromatography. A
ISSN: 1873-3778
Titre abrégé: J Chromatogr A
Pays: Netherlands
ID NLM: 9318488

Informations de publication

Date de publication:
16 Aug 2022
Historique:
received: 21 04 2022
revised: 26 06 2022
accepted: 01 07 2022
pubmed: 13 7 2022
medline: 3 8 2022
entrez: 12 7 2022
Statut: ppublish

Résumé

Glycans play important roles in the activity and function of monoclonal antibodies (mAbs). In this study, an isotope labeling method for the relative quantitative analysis of glycans in cetuximab, a chimeric human/mouse IgG1 monoclonal antibody that specifically targets epidermal growth factor receptor, via hydrophilic interaction LC-ultra-high-performance LC-HRMS was established based on Pronase E digestion. To this aim, novel isotope MS probes, i.e., 3-benzoyl-2-oxothiazolidine-4-carboxylic acid (d0-BOTC) and 3-(2,3,4,5,6-pentadeuterio-benzoyl)-2-oxothiazolidine-4-carboxylate acid (d5-BOTC), which include a carboxyl group to target the amino functional group in glycosylamine, were developed. The nonspecific Pronase E enzyme could simultaneously digest the peptide bound to the N- and O-glycans into glycosylamine having only one amino acid. Since the mass difference between the light- and heavy-labeled glycans was 5.0 Da, the relative abundance of their MS peaks was used to achieve the qualitative and relative quantitative analysis of glycans. Sialylglycopeptide was used as a complex glycan model to validate the accuracy of the method. The results demonstrated the good linearity (R

Identifiants

pubmed: 35820231
pii: S0021-9673(22)00495-2
doi: 10.1016/j.chroma.2022.463302
pii:
doi:

Substances chimiques

Polysaccharides 0
Pronase EC 3.4.24.-
Cetuximab PQX0D8J21J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

463302

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Xi-Ling Li (XL)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Chengqiang Han (C)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Miao Luo (M)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Shuyun Xiao (S)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Jing Li (J)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Chenglong Yu (C)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Shengyu Cheng (S)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Yueying Jin (Y)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Yu Han (Y)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China.

Kenichiro Todoroki (K)

Laboratory of Analytical and Bio-Analytical Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

Qing Shi (Q)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China. Electronic address: shiqing418@163.com.

Jun Zhe Min (JZ)

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Pharmaceutical Analysis, College of Pharmacy, Yanbian University, and Department of Pharmacy, Yanbian University Hospital, Yanji, Jilin 133002, China. Electronic address: junzhemin23@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH